

Information and Networking Event Horizon Europe 2023 Calls Co-Funded by the Government of India (DBT)



HORIZON-HLTH-2024-DISEASE-08-20: Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential

Friday, 13 October 2023

- TITLE of talk: Resources for vaccine and antiviral research at the Viral BSI3,
 CIDR, IISc, India.
- Name of presenter: Shashank Tripathi
- Name of Organisation: Centre for Infectious Diseases Research, Indian Institute
 of Science, Bangalore
- Country: India
- Your contact details: shashankt@iisc.ac.in Tel: +91-80-2293-2284
- Your web URL: https://cidr.iisc.ac.in/shashank/

Viral BSL-3 Facility

National Centre for Preclinical evaluation of COVID-19 Vaccines

Pathogens

- SARS-CoV-2 VOCs
- Influenza A Viruses (Human, Avian)
- Flaviviruses (Dengue, Zika, JEV, WNV)

Model systems

- Cell Culture Models
- Lung primary cells and organoids
- Animal BSL3 (Syrian Hamsters, Mice)

Instruments available

- High Content Screening Platform
- FACS-Sorting Platform
- Viral genomics
- Histopathology Core

Types of Studies

- Vaccine Efficacy studies
- Antiviral Testing studies
- Materials and Device Testing












International Clients


















Indian Clients




- Respiratory Viruses (Influenza, Coronaviruses)
- Mosquito-Borne Viruses (Dengue, Zika, JEV, WNV)
- Virus-Host Interactions, Antiviral & Vaccines
- Viral Cell culture and animal models
- Preclinical Efficacy Studies
- Viral genomics and Evolution
- Lung Organoid models
- Part of ENDFLU Indo-Euro Consortium for developing broadly protective Influenza A virus vaccines

Research Highlights



Graphical Abstract
Narayan et.al, Cell Reports Medicine 2023

Discovery of Picolinic Acid as a Broad-Spectrum antiviral against enveloped viruses including Influenza, SARS-CoV-2 and Flaviviruses.



Graphical Abstract
Biji et.al, EBiomedicine 2021

Discovery of nasal swab-based Prognostic Signature of COVID-19 and FDA-approved antiviral against SARS-CoV-2.

Selected Publications

- "Picolinic Acid is a broad-spectrum inhibitor of enveloped virus entry that restricts SARS-CoV-2 and Influenza A Virus in vivo." Rohan Narayan,Shashank Tripathi. Cell Reports Medicine, (2023).
- "Enhanced recombination among Omicron subvariants of SARS-CoV-2 contributes to viral immune escape." Rishad Shiraz, Shashank Tripathi. Journal of Medical Virology, (2023).
- "Efficient Elimination of Airborne Pathogens: A Study on aerosolized Mycobacterium tuberculosis and SARS-CoV-2 using ZeBox Technology." Rohan Narayan.... Shashank Tripathi, and Santanu Datta. Journal of Hospital Infection (2022).
- "Drug targeting Nsp1-ribosomal complex shows antiviral activity against SARS-CoV-2." Afsar, Mohammad.... Shashank Tripathi, and Tanweer Hussain. Elife 11 (2022)
- "Identification of COVID-19 prognostic markers and therapeutic targets through metaanalysis and validation of Omics data from nasopharyngeal samples". Abhijith Biji,Shashank Tripathi. EBioMedicine, (2021)
- "A stabilized, monomeric, Receptor Binding Domain elicits high-titer neutralizing antibodies against all SARS-CoV-2 variants of concern". Shahbaz Ahmed, ...Raghavan Varadarajan. Frontiers in Immunology (2021).
- "Restriction factor compendium for influenza A virus reveals a mechanism for evasion of autophagy". Laura Martin-Sancho, Shashank Tripathi...Sumit K Chanda. Nature Microbiology. (2021)

Contact details

Shashank Tripathi

Faculty In-Charge, Viral BSI3 facility, Centre for Infectious Diseases Research https://cidr.iisc.ac.in/viral-bsl-3-2/

Head, Emerging Viral Pathogens Lab, Centre for Infectious Diseases Research https://cidr.iisc.ac.in/shashank/

Assistant Professor, Microbiology and Cell Biology https://mcbl.iisc.ac.in/shashank-tripathi/

Indian Institute of Science, Bangalore, India (Academic Institution, Govt. Funded)
https://iisc.ac.in/

shashankt@iisc.ac.in Tel: +91-80-2293-2284